Merus (MRUS) Citi's 2025 Virtual Oncology Leadership Summit summary

Company overview and portfolio

• Focuses on oncology with a portfolio of fully owned and partnered multi-specific antibodies, leveraging proprietary Multiclonics technology for innovative, clinically active molecules.

• Notable assets include petosemtamab (EGFR-LGR5 bispecific), Bizengri (HER2/HER3 bispecific, FDA approved), and MCLA-129 (EGFR/c-MET bispecific).

• Strategic partnerships with Incyte, Loxo, Gilead, and others support a robust pipeline and future revenue opportunities.

Petosemtamab clinical progress and regulatory milestones

• Petosemtamab received two FDA breakthrough therapy designations: one for monotherapy and another for combination with pembrolizumab in first-line recurrent metastatic head and neck cancer.

• Phase III trials are ongoing in both first- and second-/third-line head and neck cancer, with strong KOL support and large commercial potential.

• Breakthrough designation enables senior FDA engagement, regulatory flexibility, and potential for accelerated approval based on early endpoints.

Clinical data and efficacy highlights

• ASCO 2024 data showed a 67% response rate for petosemtamab plus pembrolizumab in 24 patients, compared to 19-25% for Keytruda alone in historical controls.

• Durable responses observed, with most responders still on treatment past four months; further data updates expected later this year.

• Phase III trials aim for substantial enrollment by end of 2025, with potential for accelerated approval based on overall response rate and durability.